<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474363</article-id><article-id pub-id-type="pmcid-ver">PMC12474363.1</article-id><article-id pub-id-type="pmcaid">12474363</article-id><article-id pub-id-type="pmcaiid">12474363</article-id><article-id pub-id-type="pmid">41012154</article-id><article-id pub-id-type="doi">10.3390/vaccines13090951</article-id><article-id pub-id-type="publisher-id">vaccines-13-00951</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Experimental Efficacy of a Novel Combined Vaccine of Porcine Circovirus Types 2a/d, <italic toggle="yes">Mycoplasma hyopneumoniae</italic> and <italic toggle="yes">M. hyorhinis</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Suh</surname><given-names initials="J">Jeongmin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-13-00951" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ham</surname><given-names initials="S">Sehyeong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-vaccines-13-00951" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Na</surname><given-names initials="H">Hyejin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-vaccines-13-00951" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>You</surname><given-names initials="Y">Youngkook</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-vaccines-13-00951" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Park</surname><given-names initials="B">Bumsoo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af2-vaccines-13-00951" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chae</surname><given-names initials="C">Chanhee</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-vaccines-13-00951" ref-type="aff">1</xref><xref rid="c1-vaccines-13-00951" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-13-00951"><label>1</label>Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Gwanak-ro 1, Gwanak-gu, Seoul 08826, Republic of Korea; <email>wayne21818@gmail.com</email> (J.S.); <email>hsh6926@snu.ac.kr</email> (S.H.); <email>skwls1212@snu.ac.kr</email> (H.N.)</aff><aff id="af2-vaccines-13-00951"><label>2</label>CARESIDE Co., Ltd., Seongnam-si 13209, Republic of Korea; <email>careside@careside.co.kr</email> (Y.Y.); <email>pbs1776@gmail.com</email> (B.P.)</aff><author-notes><corresp id="c1-vaccines-13-00951"><label>*</label>Correspondence: <email>swine@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>13</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497676</issue-id><elocation-id>951</elocation-id><history><date date-type="received"><day>01</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>02</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-13-00951.pdf"/><abstract><p>Background: The efficacy of a novel combined vaccine targeting porcine circovirus types 2a/d (PCV2a/d), <italic toggle="yes">Mycoplasma hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> was evaluated in a controlled challenge study. Methods: A total of 45 pigs were randomly allocated into nine groups (five pigs per group). Vaccinated groups received a single 2 mL intramuscular dose of the combined vaccine and were subsequently challenged with PCV2a, PCV2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic>. Unvaccinated groups received a single 2 mL intramuscular dose of phosphate-buffered saline (0.01 M, pH 7.4). Growth performance, systemic adaptive immune (humoral and cellular) responses, viremia, laryngeal and nasal mycoplasma loads, and histopathological lesions were assessed. Results: Vaccinated pigs exhibited enhanced growth performance and elicited systemic immune responses, including both humoral and cellular immunity, against all four pathogens. Vaccination also significantly reduced viremia, mycoplasmal loads in laryngeal and nasal swabs, and the severity of associated lesions compared with unvaccinated controls. Conclusions: These results indicated that the combined vaccine was efficacious and conferred protection against PCV2a, PCV2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> challenge under experimental conditions. This combined vaccine represented an effective strategy to enhance growth performance and control complex co-infection in swine populations.</p></abstract><kwd-group><kwd>enzootic pneumonia</kwd><kwd><italic toggle="yes">Mycoplasma hyopneumoniae</italic></kwd><kwd><italic toggle="yes">Mycoplasma hyorhinis</italic></kwd><kwd>porcine circovirus type 2a</kwd><kwd>porcine circovirus type 2d</kwd><kwd>porcine respiratory disease complex</kwd><kwd>vaccine</kwd></kwd-group><funding-group><award-group><funding-source>Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine</funding-source><award-id>550-20210125</award-id></award-group><award-group><funding-source>BK21 FOUR Future Veterinary Medicine Leading Education and Research Center</funding-source></award-group><funding-statement>This research was supported by contract research funds (Grant no. 550-20210125, CARESIDE CO., LTD) of the Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine and by the BK21 FOUR Future Veterinary Medicine Leading Education and Research Center.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00951"><title>1. Introduction</title><p>Porcine circovirus type 2 (PCV2) is the smallest circular DNA virus identified to date, yet it remains an important pathogen associated with multiple syndromes and diseases collectively referred to as porcine circovirus-associated diseases (PCVAD) [<xref rid="B1-vaccines-13-00951" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-13-00951" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-13-00951" ref-type="bibr">3</xref>]. PCVAD continues to cause significant economic losses to the global pig industry. Currently, eight distinct genotypes of PCV2 have been proposed (PCV2a to PCV2h) [<xref rid="B4-vaccines-13-00951" ref-type="bibr">4</xref>]. Of these, PCV2a, PCV2b, and PCV2d are the most prevalent, with PCV2d predominating in most of swine-producing countries [<xref rid="B4-vaccines-13-00951" ref-type="bibr">4</xref>].</p><p><italic toggle="yes">Mycoplasma hyopneumoniae</italic> is the primary etiological agent of enzootic pneumonia and a key contributor to the porcine respiratory disease complex (PRDC), an economically important condition in pigs worldwide [<xref rid="B5-vaccines-13-00951" ref-type="bibr">5</xref>]. <italic toggle="yes">M. hyorhinis</italic> is recognized as a major cause of polyserositis and arthritis [<xref rid="B5-vaccines-13-00951" ref-type="bibr">5</xref>]. More recently, <italic toggle="yes">M. hyorhinis</italic> has emerged an important concern in swine production due to its association with increased morbidity and mortality in the postweaning period (personal observation, Chae).</p><p>Vaccination with a combination product targeting PCV2 and <italic toggle="yes">M. hyopneumoniae</italic> combination product is widely practiced worldwide to control the two pathogens, particularly in Asian pig-rearing countries. In general, PCV2 vaccines provide better protection against homologous genotypes than against heterologous challenge strains [<xref rid="B6-vaccines-13-00951" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-13-00951" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00951" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-13-00951" ref-type="bibr">9</xref>], accumulating evidence suggest that they are &#8220;leaky vaccines&#8221; [<xref rid="B10-vaccines-13-00951" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00951" ref-type="bibr">11</xref>]. Most commercially available PCV2 vaccines are still based on PCV2a or PCV2b, whereas PCV2d has become the predominant circulating field genotype in many Asian countries, including China, Korea, Taiwan, Thailand, and Vietnam [<xref rid="B12-vaccines-13-00951" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00951" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-13-00951" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00951" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00951" ref-type="bibr">16</xref>]. Consequently, there is a need for commercial vaccines incorporating PCV2d to achieve more effective control under current field conditions.</p><p>Recently, a novel commercial combined vaccine containing PCV2a, PCV2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> was introduced to the Korean market, where PCV2d predominates and cases of polyserositis caused by <italic toggle="yes">M. hyorhinis</italic> is increasing. The objective of the present study was to evaluate the efficacy of this novel combined vaccine in conferring protection against experimental challenge with PCV2a, PCV2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic>.</p></sec><sec id="sec2-vaccines-13-00951"><title>2. Materials and Methods</title><sec id="sec2dot1-vaccines-13-00951"><title>2.1. Animals</title><p>Forty-five clinically healthy piglets, aged 18 days, were obtained from a commercial sow farm. The source herd had been confirmed free of <italic toggle="yes">Mycoplasma hyopneumoniae</italic> and porcine reproductive and respiratory syndrome virus (PRRSV) through routine serological monitoring, supported by long-term clinical observation and slaughter checks. At the time of arrival, all piglets underwent serological screening and tested negative for PCV2 (Porcine Circovirus type 2 Antibody Test, BioChek B.V., Reeuwijk, The Netherlands), PRRSV (HerdChek PRRS X3 Ab test, IDEXX Laboratories Inc., Westbrook, ME, USA), <italic toggle="yes">Mycoplasma hyopneumoniae</italic> (ID Screen<sup>&#174;</sup>&#160;<italic toggle="yes">Mycoplasma hyopneumoniae</italic> Competition ELISA, ID.Vet, Grabels, France), and <italic toggle="yes">M. hyorhinis</italic> (in-house ELISA). In addition, real-time polymerase chain reaction (PCR) assays confirmed the absence of PCV2 and PRRSV viremia, as well as <italic toggle="yes">M. hyopneumoniae</italic> and <italic toggle="yes">M. hyorhinis</italic> in the pharyngeal samples.</p></sec><sec id="sec2dot2-vaccines-13-00951"><title>2.2. Vaccine</title><p>A combined vaccine, XENOVAX PCM4 (CARESIDE CO., LTD., Seongnam-si, Gyeonggi-do, Republic of Korea, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.careside.co.kr">http://www.careside.co.kr</uri>), consists of four recombinant proteins, PCV2d, PCV2a, T-BLS (<italic toggle="yes">Brucella lumazine</italic> synthase + T-cell; &#8805;RP 1.0), and <italic toggle="yes">M. hyopneumoniae</italic> p65 protein-together with two inactivated whole-cell bacterin, <italic toggle="yes">M. hyopneumoniae</italic> (&#8805;RP 1.0) and <italic toggle="yes">M. hyorhinis</italic> (&#8805;RP 1.0). The PCV2a and PCV2d capsid proteins were expressed in an <italic toggle="yes">Escherichia coli</italic> system and self-assembled into virus-like particles that are morphologically indistinguishable from native PCV2. The vaccine was adjuvanted with 12% of Emulcigen_BCL (MVP adjuvants, Omaha, NE, USA) and Quil-A (100 &#956;g/mL, InvivoGen, Hong Kong, China). XENOVAX PCM4 is administered intramuscularly as a single 2.0 mL dose from three weeks of age onward.</p></sec><sec id="sec2dot3-vaccines-13-00951"><title>2.3. Experimental Design</title><p>All animal procedures were reviewed and approved by the Seoul National University Institutional Animal Care and Use, and Ethics Committee (SNU-211222-3-1). The challenge study was conducted incompliance with the Republic of Korea&#8217;s Animal, Plant &amp; Fisheries Quarantine &amp; Inspection Agency (QIA, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.qia.go.kr">http://www.qia.go.kr</uri>) registration guidelines. A total of 45 pigs were randomly allocated into nine experimental groups (five pigs per group; two males and three females) (<xref rid="vaccines-13-00951-t001" ref-type="table">Table 1</xref>). Each group was kept in a separate isolation room under uniform housing conditions, with unrestricted access to feed and water.</p><p>At &#8722;21 days post challenge (dpc, 21 days of age), pigs in the Vac/ChMhp, Vac/Ch2dMhr, Vac/Ch2a, and Vac/Ch2d groups were intramuscularly immunized with 2.0 mL of the combined vaccine (Xenovax PCM4, Careside, Seongnam-si, Republic of Korea). Pigs in the UnVac/ChMhp, UnVac/Ch2dMhr, UnVac/Ch2a, UnVac/Ch2d, and UnVac/UnCh groups received an intramuscular injection of 2.0 mL of phosphate-buffered saline (PBS, 0.01 M, pH 7.4).</p><p>At 0 days post challenge (42 days of age), pigs in the Vac/ChMhp and UnVac/ChMhp groups were challenged with <italic toggle="yes">M. hyopneumoniae</italic> (strain <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="SNU98703">SNU98703</ext-link>). Prior to inoculation, pigs were anesthetized intramuscularly with a combination of 2.2 mg/kg xylazine hydrochloride (Rompun, Bayer Healthcare, Shawnee Mission, KS, USA), 2.2 mg/kg tiletamine hydrochloride, and 2.2 mg/kg zolazepam hydrochloride (Zoletil 50, Virbac, Carros, France). The challenge was performed intratracheally with 7 mL of <italic toggle="yes">M. hyopneumoniae</italic> (strain <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="SNU98703">SNU98703</ext-link>) culture medium containing 10<sup>7</sup> color changing units/mL, following the procedure described previously [<xref rid="B17-vaccines-13-00951" ref-type="bibr">17</xref>].</p><p>Pigs in the Vac/Ch2dMhr and UnVac/Ch2dMhr groups were first challenged with PCV2d (SNUVR202003 strain, GenBank no. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MZ440695">MZ440695</ext-link>, 5th passage in PCV-free PK-15 cell lines), followed five hours later by <italic toggle="yes">M. hyorhinis</italic> (strain CS401-001). For the PCV2d challenge, pigs received 3 mL of inoculum intranasally containing 1.2 &#215; 10<sup>5</sup> TCID<sub>50</sub>/mL (50% tissue culture infective dose/mL). Five hours post-inoculation, pigs were anesthetized intramuscularly as described above and subsequently challenged with <italic toggle="yes">M. hyorhinis</italic> (strain CS401-001) by intratracheal (2 mL) and intraperitoneal (2 mL) inoculation of culture medium containing 10<sup>9</sup> color changing units/mL, following previously established protocols [<xref rid="B18-vaccines-13-00951" ref-type="bibr">18</xref>].</p><p>Pigs in the Vac/Ch2a and UnVac/Ch2a groups were challenged intranasally with a 3 mL of inoculum containing 1.2 &#215; 10<sup>5</sup> TCID<sub>50</sub>/mL of PCV2a (SNUVR100032 strain, GenBank no. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="KF871067">KF871067</ext-link>, 5th passage in PCV-free PK-15 cell lines). Similarly, pigs in the Vac/Ch2d and UnVac/Ch2d groups were challenged intranasally with a 3 mL of inoculum containing 1.2 &#215; 10<sup>5</sup> TCID<sub>50</sub>/mL of PCV2d (SNUVR202003 strain, GenBank no. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="MZ440695">MZ440695</ext-link>, 5th passage in PCV-free PK-15 cell lines).</p><p>At 21 days post challenge (63 days of age), all pigs were sedated with intravenous sodium pentobarbital and subsequently euthanized by electrocution as previously described [<xref rid="B19-vaccines-13-00951" ref-type="bibr">19</xref>]. During necropsy, tissue samples from each pig were collected, fixed in 10% neutral buffered formalin, and processed for paraffin embedding.</p></sec><sec id="sec2dot4-vaccines-13-00951"><title>2.4. Collection of Samples</title><p>Sampling involved the collection of blood, nasal swabs, and laryngeal swabs from all animals at &#8722;21, 0, 7, 14, and 21 days post challenge.</p></sec><sec id="sec2dot5-vaccines-13-00951"><title>2.5. Clinical Scoring</title><p>Pigs were monitored daily for clinical signs, and severity scores were recorded weekly using a defined scale: 0 (normal), 1 (rough haircoat), 2 (rough haircoat and dyspnea), 4 (severe dyspnea and abdominal breathing), and 6 (death). Scoring was performed by examiners blinded to treatment groups.</p></sec><sec id="sec2dot6-vaccines-13-00951"><title>2.6. Growth Performance</title><p>Body weight was recorded for each pig at three time points: &#8722;21 (corresponding to 21 days of age), 0 (42 days of age), and 21 (63 days of age) days post challenge. Average daily weight gain (ADWG; g/pig/day) was calculated for three intervals: (i) from 21 to 42 days of age, (ii) from 42 to 63 days of age, and (iii) from 21 to 63 days of age. For each interval, ADWG was derived as (final weight &#8722; initial weight)/number of days.</p></sec><sec id="sec2dot7-vaccines-13-00951"><title>2.7. PCV2 DNA Quantification in Serum Samples</title><p>Serum DNA was isolated using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer&#8217;s instructions. Real-time PCR was used to quantify genomic copy numbers of PCV2a and PCV2d [<xref rid="B20-vaccines-13-00951" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00951" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot8-vaccines-13-00951"><title>2.8. M. hyopneumoniae DNA Quantification in Laryngeal Samples</title><p>DNA was extracted from laryngeal samples using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer&#8217;s instructions. Real-time PCR was used to quantify genomic copy numbers of <italic toggle="yes">M. hyopneumoniae</italic> [<xref rid="B22-vaccines-13-00951" ref-type="bibr">22</xref>].</p></sec><sec id="sec2dot9-vaccines-13-00951"><title>2.9. M. hyorhinis DNA Quantification in Nasal Samples</title><p>DNA was extracted from nasal samples using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer&#8217;s instruction. Real-time PCR was used to quantify genomic copy numbers of <italic toggle="yes">M. hyorhinis</italic> [<xref rid="B23-vaccines-13-00951" ref-type="bibr">23</xref>].</p></sec><sec id="sec2dot10-vaccines-13-00951"><title>2.10. PCV2 Serology</title><p>Serum antibody responses to PCV2 were evaluated using a commercial enzyme-linked immunosorbent assay (ELISA; BioChek B.V., Reeuwijk, The Netherlands). According to the manufacturer&#8217;s criteria, samples with the sample-to-positive (S/P) ratio of &#8805;0.5 were considered positive. In addition, serum viral neutralization tests were performed in 96-well microtitration plates using PK-15 cells as the indicator cells [<xref rid="B24-vaccines-13-00951" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00951" ref-type="bibr">25</xref>].</p></sec><sec id="sec2dot11-vaccines-13-00951"><title>2.11. M. hyopneumoniae Serology</title><p>Antibody responses to <italic toggle="yes">Mycoplasma hyopneumoniae</italic> were evaluated in serum samples using a commercially available competitive ELISA kit (ID Screen<sup>&#174;</sup>&#160;<italic toggle="yes">Mycoplasma hyopneumoniae</italic> Competition ELISA, ID.Vet, Grabels, France) following the manufacturer&#8217;s protocol. Samples with the sample-to-negative (S/N) ratio &#8804; 0.5 were considered positive.</p></sec><sec id="sec2dot12-vaccines-13-00951"><title>2.12. M. hyorhinis Serology</title><p>An in-house ELISA was performed to detect <italic toggle="yes">Mycoplasma hyorhinis</italic>-specific antibodies in serum. Purified p70 protein was diluted in carbonate-bicarbonate buffer and coated onto 96-well MaxiSorp plates (Nunc, Invitrogen, Carlsbad, CA, USA) at 0.1 ng per well, followed by overnight incubation at 4 &#176;C. Plates were then washed three times with PBST (0.05% Tween 20 in PBS) between incubation steps. Blocking was performed with 50 &#181;L/well of 2% skim milk in PBST for 1 h at 37 &#176;C. Serum samples and controls, diluted 1:100 in PBST, were added in duplicate (50 &#181;L per well) and incubated for 1 h at 37 &#176;C. Goat anti-swine IgG conjugated to peroxidase (KPL, Seracare Life Sciences, Milford, MA, USA) was added at a 1:2000 dilution in 0.2% skim milk and incubated for 1 h at 37 &#176;C. After washing, plates were developed with 50 &#181;L/well of SureBlue TMB substrate (Seracare) for 10 min at room temperature, followed by 50 &#181;L/well stop solution (Seracare). Absorbance at 450 nm was measured within 15 min using a microplate reader. Samples with a sample-to-positive (S/P) ratio &#8805; 0.3 were classified as positive.</p></sec><sec id="sec2dot13-vaccines-13-00951"><title>2.13. Quantification of Antigen-Specific IFN-&#947;-Secreting Cells</title><p>An enzyme-linked immunospot (ELISpot) assay was performed to quantify interferon-&#947; secreting cells (IFN-&#947;-SC) specific to PCV2a, PCV2d, <italic toggle="yes">Mycoplasma hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic>. Peripheral blood mononuclear cells (PBMC) were stimulated with the respective challenge strains. [<xref rid="B21-vaccines-13-00951" ref-type="bibr">21</xref>,<xref rid="B26-vaccines-13-00951" ref-type="bibr">26</xref>]. Results were expressed as the number of IFN-&#947;-SC per million PBMC.</p></sec><sec id="sec2dot14-vaccines-13-00951"><title>2.14. Pathology</title><p>For gross lesion scoring, two pathologists at the Seoul National University, blinded to treatment groups, evaluated the extent of lung involvement and calculated the percentage of the lung affected by pneumonia [<xref rid="B27-vaccines-13-00951" ref-type="bibr">27</xref>]. Lesions of the hepatic serosa were assessed separately based on the percentage of affected parts (0 = none; 1 = 0&#8211;30%; 2 = 31&#8211;60%; 3 = 61&#8211;100%), following previously described methods [<xref rid="B18-vaccines-13-00951" ref-type="bibr">18</xref>].</p><p>For microscopic evaluation, lung, lymphoid, and hepatic tissue sections were evaluated independently by two blinded veterinary pathologists. Lung lesions were scored based on the presence of peribronchial and peribronchiolar lymphoid hyperplasia, and degree of inflammation in the lamina propria of bronchi and bronchioles, using a scale of 0 to 6 (0 = normal; 1 = mild multifocal; 2 = mild diffuse; 3 = moderate multifocal; 4 = moderate diffuse; 5 = severe multifocal; 6 = severe diffuse) [<xref rid="B28-vaccines-13-00951" ref-type="bibr">28</xref>]. Real-time PCR was performed to confirm mycoplasmal pneumonia as previously described [<xref rid="B22-vaccines-13-00951" ref-type="bibr">22</xref>]. Lymphoid lesions were scored based on the presence of lymphoid depletion and inflammation, using a scale of 0 to 5 (0 = normal; 1 = mild lymphoid depletion; 2 = mild to moderate lymphoid depletion and histiocytic replacement; 3 = moderate diffuse lymphoid depletion and histiocytic replacement; 4 = moderate to severe lymphoid depletion and histiocytic replacement; 5 = severe lymphoid depletion and histiocytic replacement) [<xref rid="B29-vaccines-13-00951" ref-type="bibr">29</xref>]. Hepatic lesions were assessed for fibrinous perihepatitis using a scoring scale of 0 to 6 (0 = normal; 1 = mild multifocal; 2 = mild diffuse; 3 = moderate multifocal; 4 = moderate diffuse; 5 = severe multifocal; 6 = severe diffuse).</p></sec><sec id="sec2dot15-vaccines-13-00951"><title>2.15. Statistical Analysis</title><p>Real-time PCR results and neutralizing antibody titers were log-transformed to base 10 and base 2, respectively, before analysis. Normality was assessed using the Shapiro&#8211;Wilk test. If the data were normally distributed, one-way ANOVA was performed to compare groups at each time point, followed by Tukey&#8217;s post hoc test. For non-normally distributed data, the Kruskal&#8211;Wallis test was applied, and statistically significant results were further analyzed using the Mann&#8211;Whitney U test. A <italic toggle="yes">p</italic>-value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vaccines-13-00951"><title>3. Results</title><sec id="sec3dot1-vaccines-13-00951"><title>3.1. Decreased Respiratory Clinical Signs</title><p>Within the <italic toggle="yes">M. hyopneumoniae</italic> challenged groups, pigs in the Vac/ChMhp group had significantly decreased the respiratory clinical scores (<italic toggle="yes">p</italic> &lt; 0.05) at 14 and 21 days post challenge compared with pigs in the UnVac/ChMhp group. Within the PCV2a challenged groups, pigs in the Vac/Ch2a experienced a significant decrease in respiratory clinical scores (<italic toggle="yes">p</italic> &lt; 0.05) at 14 and 21 days post challenge compared with pigs in the UnVac/Ch2a group. Within the PCV2d challenged groups, pigs in the Vac/Ch2d had a significant decrease in respiratory clinical scores (<italic toggle="yes">p</italic> &lt; 0.05) at 14 and 21 days post challenge compared with pigs in the UnVac/Ch2d group. Within the PCV2d and <italic toggle="yes">M. hyorhinis</italic> challenged groups, pigs in the Vac/Ch2dMhr had a significant decrease in respiratory clinical scores (<italic toggle="yes">p</italic> &lt; 0.05) at 14 and 21 days post challenge compared with pigs in the UnVac/Ch2dMhr group.</p></sec><sec id="sec3dot2-vaccines-13-00951"><title>3.2. Improved Growth Performance</title><p>The body weight of the pigs did not differ significantly among 9 groups at &#8722;21 days post challenge (21 days of age; the time of vaccination) and 0 (42 days of age; the time of challenge) days post challenge. Within the <italic toggle="yes">M. hyopneumoniae</italic> challenged pigs, Vac/ChMhp treatment resulted in significant (<italic toggle="yes">p</italic> &lt; 0.05) improvement in body weight at 21 days post challenge (63 days of age) compared with pigs in the UnVac/ChMhp group. Pigs in the Vac/ChMhp group had a significant improvement in their ADWG (<italic toggle="yes">p</italic> &lt; 0.05) from 0 (42 days of age) to 21 (63 days of age) days post challenge and from &#8722;21 (21 days of age) to 21 (63 days of age) days post challenge compared with pigs in the UnVac/ChMhp group. Within the PCV2d and <italic toggle="yes">M. hyorhinis</italic> challenged group, pigs in the Vac/Ch2dMhr had a significant improvement in body weight (<italic toggle="yes">p</italic> &lt; 0.05) at 21 days post challenge (63 days of age) compared with pigs in the UnVac/Ch2dMhr group. Pigs in the Vac/Ch2dMhr group had a significant improvement in ADWG (<italic toggle="yes">p</italic> &lt; 0.05) from 0 (42 days of age) to 21 (63 days of age) days post challenge and from &#8722;21 (21 days of age) to 21 (63 days of age) days post challenge compared with pigs in the UnVac/Ch2dMhr group (<xref rid="vaccines-13-00951-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec3dot3-vaccines-13-00951"><title>3.3. PCV2 DNA Genomic Copy Numbers in Serum Samples</title><p>In pigs challenged with PCV2a, no PCV2a DNA was detected in serum at either the time of vaccination or viral challenge. A significant reduction (<italic toggle="yes">p</italic> &lt; 0.05) in serum PCV2a genomic copies was observed in the vaccinated and challenged group (Vac/Ch2a) at 14 and 21 days post challenge compared to the unvaccinated and challenged group (UnVac/Ch2a) (<xref rid="vaccines-13-00951-f001" ref-type="fig">Figure 1</xref>a). Similarly, in the PCV2d challenge group, serum samples were negative for PCV2d DNA prior to both vaccination and challenge. Vaccinated pigs (Vac/Ch2d) exhibited significantly (<italic toggle="yes">p</italic> &lt; 0.05) lower PCV2d DNA levels at 14 and 21 days post challenge relative to the UnVac/Ch2d group (<xref rid="vaccines-13-00951-f001" ref-type="fig">Figure 1</xref>b). Within the PCV2d and <italic toggle="yes">M. hyorhinis</italic>-challenged pigs, no PCV2d DNA was present in serum prior to treatment. The experiment resulted in a significant (<italic toggle="yes">p</italic> &lt; 0.05) reduction in the amount of PCV2d DNA measured from serum of the vaccinated-challenged groups (Vac/Ch2dMhr) at 7, 14, and 21 days post challenge when compared with their unvaccinated counterparts (UnVac/Ch2dMhr) (<xref rid="vaccines-13-00951-f001" ref-type="fig">Figure 1</xref>c). Throughout the study, serum samples from the negative control group (UnVac/UnCh) remained free of detectable PCV2a and PCV2d DNA.</p></sec><sec id="sec3dot4-vaccines-13-00951"><title>3.4. M. hyopneumoniae DNA Copy Numbers in Laryngeal Samples</title><p>At the time of vaccination and challenge, no <italic toggle="yes">M. hyopneumoniae</italic> DNA was detected in laryngeal swabs from any pigs. The experiment resulted in a significant (<italic toggle="yes">p</italic> &lt; 0.05) reduction in the amount of laryngeal <italic toggle="yes">M. hyopneumoniae</italic> DNA from the vaccinated-challenged group (Vac/ChMhp) at 14 and 21 days post challenge compared to those in the unvaccinated and challenged group (UnVac/ChMhp). Throughout the experiment, no <italic toggle="yes">M. hyopneumoniae</italic> DNA was identified in laryngeal samples from the negative control group (UnVac/UnCh) (<xref rid="vaccines-13-00951-f002" ref-type="fig">Figure 2</xref>a).</p></sec><sec id="sec3dot5-vaccines-13-00951"><title>3.5. M. hyorhinis DNA Copy Numbers in Nasal Samples</title><p>At the time of vaccination and challenge, <italic toggle="yes">M. hyorhinis</italic> DNA was undetectable in nasal swabs from all pigs. The experiment resulted in a significant (<italic toggle="yes">p</italic> &lt; 0.05) reduction in the amount of nasal <italic toggle="yes">M. hyorhinis</italic> DNA of vaccinated-challenged groups (Vac/ChMhr) at 14 and 21 days post challenge compared to the unvaccinated and challenged group (UnVac/ChMhr). No <italic toggle="yes">M. hyorhinis</italic> DNA was detected in nasal samples from the negative control group (UnVac/UnCh) throughout the study (<xref rid="vaccines-13-00951-f002" ref-type="fig">Figure 2</xref>b).</p></sec><sec id="sec3dot6-vaccines-13-00951"><title>3.6. Host Immune Responses Against PCV2</title><p>From 0 to 21 days post-challenge, the vaccinated and challenged groups (Vac/Ch2a, Vac/Ch2d, and Vac/Ch2dMhr) exhibited significantly higher (<italic toggle="yes">p</italic> &lt; 0.05) PCV2 ELISA S/P ratios compared to their unvaccinated counterparts (UnVac/Ch2a, UnVac/Ch2d, and UnVac/Ch2dMhr) (<xref rid="vaccines-13-00951-f003" ref-type="fig">Figure 3</xref>a). PCV2a-specific neutralizing antibody (NA) titers in the vaccinated-challenged groups (Vac/Ch2a) were markedly elevated (<italic toggle="yes">p</italic> &lt; 0.05) compared to the UnVac/Ch2a group from 0 to 21 days post challenge (<xref rid="vaccines-13-00951-f003" ref-type="fig">Figure 3</xref>b). PCV2d-specific NA titers from the vaccinated-challenged groups (Vac/Ch2d and Vac/Ch2dMhr) were significantly higher (<italic toggle="yes">p</italic> &lt; 0.05) relative to the UnVac/Ch2d and UnVac/Ch2dMhr groups from 0 to 21 days post challenge (<xref rid="vaccines-13-00951-f003" ref-type="fig">Figure 3</xref>b).</p><p>PCV2a-specific IFN-&#947;-secreting cell (IFN-&#947;-SC) levels were significantly increased (<italic toggle="yes">p</italic> &lt; 0.05) in the Vac/Ch2a group from 14 to 21 days post challenge compared to the UnVac/Ch2a group. PCV2d-specific IFN-&#947;-SC responses in the Vac/Ch2d group were also significantly elevated (<italic toggle="yes">p</italic> &lt; 0.05) from 0 to 21 days post challenge relative to the UnVac/Ch2d group. PCV2d-specific IFN-&#947;-SC responses Vac/Ch2dMhr group were significantly elevated (<italic toggle="yes">p</italic> &lt; 0.05) compared to the UnVac/Ch2dMhr group from 14 to 21 days post challenge. Throughout the study, the negative control group (UnVac/UnCh) showed only baseline PCV2 ELISA S/P ratios and IFN-&#947;-SC counts, and no detectable PCV2d-specific NA titers (<xref rid="vaccines-13-00951-f003" ref-type="fig">Figure 3</xref>c).</p></sec><sec id="sec3dot7-vaccines-13-00951"><title>3.7. Host Immune Responses Against M. hyopneumoniae</title><p>The vaccinated-challenged group (Vac/ChMhp) showed significantly reduced S/N ratios (<italic toggle="yes">p</italic> &lt; 0.05) in the <italic toggle="yes">M. hyopneumoniae</italic>-specific ELISA compared to their unvaccinated-challenged counterparts (UnVac/ChMhp) from 0 to 21 days post challenge (<xref rid="vaccines-13-00951-f004" ref-type="fig">Figure 4</xref>a). IFN-&#947;-secreting cell (IFN-&#947;-SC) counts specific to <italic toggle="yes">M. hyopneumoniae</italic> in the Vac/ChMhp group were markedly higher (<italic toggle="yes">p</italic> &lt; 0.05) compared to the UnVac/ChMhp group from 0 and 21 days post challenge (<xref rid="vaccines-13-00951-f004" ref-type="fig">Figure 4</xref>b). Both <italic toggle="yes">M. hyopneumoniae</italic>-specific S/N ratios and IFN-&#947;-SC levels remained at baseline in the negative control group (UnVac/UnCh) throughout the study.</p></sec><sec id="sec3dot8-vaccines-13-00951"><title>3.8. Host Immune Responses Against M. hyorhinis</title><p>Pigs in the vaccinated-challenged group (Vac/Ch2dMhr) exhibited significantly elevated S/P ratios (<italic toggle="yes">p</italic> &lt; 0.05) in the <italic toggle="yes">M. hyorhinis</italic>-specific ELISA compared to the unvaccinated group (UnVac/Ch2dMhr) from 0 to 21 days post challenge (<xref rid="vaccines-13-00951-f004" ref-type="fig">Figure 4</xref>c). IFN-&#947;-SC responses to <italic toggle="yes">M. hyorhinis</italic> in Vac/Ch2dMhr were also significantly increased (<italic toggle="yes">p</italic> &lt; 0.05) than UnVac/Ch2dMhr counterparts from 7 and 21 dpc (<xref rid="vaccines-13-00951-f004" ref-type="fig">Figure 4</xref>d). As with other markers, baseline values of <italic toggle="yes">M. hyorhinis</italic>-specific ELISA S/P ratios and IFN-&#947;-SC responses were observed in the negative control animals (UnVac/UnCh) across all time points.</p></sec><sec id="sec3dot9-vaccines-13-00951"><title>3.9. Reduced Pathological Lesion Severity</title><p>At 21 dpc, pigs in both the Vac/ChMhp and UnVac/ChMhp groups exhibited gross lung lesions, predominantly consisting of sharply demarcated, firm, dark-red to purple areas of consolidation (<xref rid="vaccines-13-00951-f005" ref-type="fig">Figure 5</xref>a,b). Histologically, these lesions were characterized by marked peribronchiolar lymphoid hyperplasia (<xref rid="vaccines-13-00951-f006" ref-type="fig">Figure 6</xref>a,b) in pigs in the Vac/ChMhp and UnVac/ChMhp groups. However, the extent of both macroscopic and microscopic pulmonary lesions was significantly diminished (<italic toggle="yes">p</italic> &lt; 0.05) in the Vac/ChMhp group compared to its unvaccinated counterparts (UnVac/ChMhp) at 21 dpc (<xref rid="vaccines-13-00951-t003" ref-type="table">Table 3</xref>).</p><p>In pigs challenged with PCV2d and <italic toggle="yes">M. hyorhinis,</italic> minimal lymphoid depletion was observed in the Vac/Ch2dMhr group (<xref rid="vaccines-13-00951-f006" ref-type="fig">Figure 6</xref>c), whereas severe diffuse lymphoid depletion with histiocytic infiltration was prominent in the UnVac/Ch2dMhr group (<xref rid="vaccines-13-00951-f006" ref-type="fig">Figure 6</xref>d). Overall, vaccinated and challenged groups (Vac/Ch2a, Vac/Ch2d, and Vac/Ch2dMhr) exhibited significantly reduced (<italic toggle="yes">p</italic> &lt; 0.05) lymphoid lesion scores in comparison to their unvaccinated-challenged counterparts (UnVac/Ch2a, UnVac/Ch2d, and UnVac/Ch2dMhr) at 21 days post challenge (<xref rid="vaccines-13-00951-t003" ref-type="table">Table 3</xref>).</p><p>Macroscopically, a minimal fibrinous perihepatic lesion was observed in pigs from the Vac/Ch2dMhr group (<xref rid="vaccines-13-00951-f005" ref-type="fig">Figure 5</xref>c). A severe fibrinous perihepatic lesion was observed in pigs from the UnVac/Ch2dMhr group (<xref rid="vaccines-13-00951-f005" ref-type="fig">Figure 5</xref>d). Microscopically, a moderate fibrinous perihepatic lesion, covered with moderate non-organized fibrin, was observed in pigs from the Vac/Ch2dMhr group (<xref rid="vaccines-13-00951-f006" ref-type="fig">Figure 6</xref>e). Severe fibrinous perihepatic lesion covered with abundant non-organized fibrin was observed in the pigs from the UnVac/Ch2dMhr group (<xref rid="vaccines-13-00951-f006" ref-type="fig">Figure 6</xref>f). Pigs in the vaccinated&#8211;challenged groups (Vac/Ch2dMhr) had significantly lower (<italic toggle="yes">p</italic> &lt; 0.05) microscopic fibrinous hepatic lesions compared to unvaccinated-challenged groups (UnVa/Ch2dMhr) at 21 days post challenge (<xref rid="vaccines-13-00951-t003" ref-type="table">Table 3</xref>). Pulmonary, lymphoid, and hepatic lesions were not observed in pigs in the negative control group (UnVac/UnCh).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-13-00951"><title>4. Discussion</title><p>The present experimental challenge study demonstrated that a novel combined vaccine containing PCV2a/2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> effectively protected pigs against challenge with these pathogens. As reported previously, infection with PCV2a or PCV2d alone does not induce PCVAD in pigs [<xref rid="B30-vaccines-13-00951" ref-type="bibr">30</xref>]. Accordingly, vaccinated pigs challenged solely with PCV2a or PCV2d did not show improved growth performance compared to unvaccinated controls. In contrast, co-infection with PCV2 and <italic toggle="yes">M. hyorhinis</italic> induces full manifestations of PCVAD [<xref rid="B18-vaccines-13-00951" ref-type="bibr">18</xref>]. Consistently, vaccinated pigs challenged with PCV2d and <italic toggle="yes">M. hyorhinis</italic> exhibited significantly better growth performance than their unvaccinated counterparts. Furthermore, since <italic toggle="yes">M. hyopneumoniae</italic> is known to cause chronic respiratory disease with growth retardation [<xref rid="B31-vaccines-13-00951" ref-type="bibr">31</xref>], vaccinated pigs challenged with <italic toggle="yes">M. hyopneumoniae</italic> also showed significant improvement in growth performance compared to unvaccinated pigs.</p><p>The combined vaccine offers effective protection againstPCV2d, the currently most clinically relevant PCV2 genotype. Although traditional PCV2a-based vaccines have provided acceptable cross-protection against PCV2d in many herds [<xref rid="B21-vaccines-13-00951" ref-type="bibr">21</xref>], their efficacy has become increasingly unreliable [<xref rid="B9-vaccines-13-00951" ref-type="bibr">9</xref>,<xref rid="B32-vaccines-13-00951" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00951" ref-type="bibr">33</xref>]. Notably, PCVAD outbreaks caused by PCV2d has been reported in herds vaccinated with PCV2a-based products [<xref rid="B32-vaccines-13-00951" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00951" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-13-00951" ref-type="bibr">34</xref>], raising concerns regarding the protective capacity of such vaccines. Accordingly, a combined vaccine containing both PCV2a and PCV2d is expected to provide broader genotypic coverage and superior protection compared to monovalent vaccines under diverse field conditions.</p><p>The clinical manifestation of PCVAD is closely associated with viral load in growing pigs. A high PCV2 viremia leads to overt clinical disease with increased mortality, whereas low viremia results in subclinical infection and impaired growth performance [<xref rid="B35-vaccines-13-00951" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00951" ref-type="bibr">36</xref>]. Thus, reduction in PCV2 viremia is considered the primary indicator of vaccine efficacy. Control of PCV2a and PCV2d viremia reflect the protective immunity elicited by vaccination, which involves both humoral (i.e., neutralizing antibodies) and cell-mediated (i.e., IFN-&#947;-SC) responses [<xref rid="B37-vaccines-13-00951" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-13-00951" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00951" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00951" ref-type="bibr">40</xref>]. In this study, the combined vaccine containing PCV2a/2d antigens induced protective immune responses, significantly reduced PCV2a and PCV2d viremia, and decreased the severity of lymphoid lesions.</p><p>In the PCV2d and <italic toggle="yes">M. hyorhinis</italic> co-infection model, the reduction in PCV2d viremia in vaccinated pigs was likely mediated by a direct antiviral immune response involving neutralizing antibodies and cell-mediated immunity. Because Mycoplasma co-infection enhances inflammation, promotes PCV2 replication, and broadens tissue distribution [<xref rid="B18-vaccines-13-00951" ref-type="bibr">18</xref>], the observed reduction in <italic toggle="yes">M. hyorhinis</italic> load may have indirectly contributed to lower PCV2 replication by mitigating local inflammation. Collectively, these results suggest that the combined vaccine exerts both direct antiviral effects against PCV2 and indirect benefits through suppression of <italic toggle="yes">M. hyorhinis</italic>-induced inflammation, thereby reducing overall viral burden and disease severity.</p><p>Vaccination induces a cellular immune response to <italic toggle="yes">M. hyopneumoniae</italic>, which plays a critical role in controlling infection [<xref rid="B41-vaccines-13-00951" ref-type="bibr">41</xref>]. Therefore, vaccination of pigs with a combined vaccine resulted in the induction of cellular immune response to <italic toggle="yes">M. hyopneumoniae</italic> and demonstrated protection by significantly lowering mycoplasmal laryngeal loads while reducing lung lesions.</p><p>In recent years, <italic toggle="yes">M. hyorhinis</italic> has been increasingly recognized as a cause of polyserositis and arthritis, contributing to elevated morbidity and mortality in pigs. Control measures, such as improved management and antimicrobial therapy, can reduce infection pressure but are not always sufficient [<xref rid="B5-vaccines-13-00951" ref-type="bibr">5</xref>]. Although detailed information on vaccine-mediated protective mechanisms against <italic toggle="yes">M. hyorhinis</italic> remains limited, the combined vaccine evaluated here elicited systemic humoral and cellular responses, reduced nasal <italic toggle="yes">M. hyorhinis</italic> loads, and lessened the severity of polyserositis. Thus, this combined vaccine may represent a valuable alternative tool to controlling <italic toggle="yes">M. hyorhinis</italic> infections in swine herds.</p><p>Only four different vaccinated-challenged groups (Vac/Ch2a, VacCh2d, Vac/Ch2dMhr, and Vac/ChMhp) were included in this study, in accordance with recommendations from the Seoul National University Institutional Animal Care and Use Committee, and the guideline of the Republic of Korea&#8217;s Animal, Plant &amp; Fisheries Quarantine &amp; Inspection Agency, to minimize animal use. A notable discrepancy exists between PCV2 genotypes circulating globally and those represented in commercial vaccines, raising concerns about inadequate protection, particularly against PCV2d. In the present study, a combined vaccine containing PCV2a/2d, <italic toggle="yes">M. hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> conferred protection in challenge models against all four pathogens. Therefore, this combined vaccine may represent an effective strategy to enhance growth performance and control complex co-infection in swine populations.</p></sec><sec sec-type="conclusions" id="sec5-vaccines-13-00951"><title>5. Conclusions</title><p>This controlled experimental challenge study demonstrated that a novel combined vaccine comprising PCV2a/2d, <italic toggle="yes">Mycoplasma hyopneumoniae</italic>, and <italic toggle="yes">M. hyorhinis</italic> effectively protected pigs against these pathogens. Vaccination significantly reduced PCV2 viremia, laryngeal and nasal mycoplasma loads, and the severity of associated lesions, while enhancing systemic immune responses and growth performance. Collectively, these findings support the combined vaccine as promising strategy for the integrated control of PCV2-associated diseases, enzootic pneumonia, and <italic toggle="yes">M. hyorhinis</italic>-related conditions, with the potential to improve overall herd health and productivity.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Designed the experiments: C.C.; writing&#8212;original draft: C.C.; writing&#8212;review and editing: J.S., S.H. and H.N.; analyzed the data: Y.Y. and B.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All of the methods were approved by the Seoul National University Institutional Animal Care and Use, and Ethics Committee (SNU-211222-3-1). During the entire experimental process, all protocols used were consistent with the rules for animal ethics.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data used to support the findings of this study are included within this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Authors Youngkook You and Bumsoo Park were employed by the company CARESIDE Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00951"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name></person-group><article-title>Porcine circovirus type 2 (PCV2) infections: Clinical signs, pathology and laboratory diagnosis</article-title><source>Virus Res.</source><year>2012</year><volume>164</volume><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2011.10.007</pub-id><pub-id pub-id-type="pmid">22056845</pub-id></element-citation></ref><ref id="B2-vaccines-13-00951"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Q.Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.M.</given-names></name></person-group><article-title>Current understanding of genomic DNA of porcine circovirus type 2</article-title><source>Virus Genes</source><year>2014</year><volume>49</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s11262-014-1099-z</pub-id><pub-id pub-id-type="pmid">25011695</pub-id></element-citation></ref><ref id="B3-vaccines-13-00951"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tischer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gelderblom</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vettermann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>M.A.</given-names></name></person-group><article-title>A very small porcine virus with circular single-stranded DNA</article-title><source>Nature</source><year>1982</year><volume>295</volume><fpage>64</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/295064a0</pub-id><pub-id pub-id-type="pmid">7057875</pub-id></element-citation></ref><ref id="B4-vaccines-13-00951"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name></person-group><article-title>Porcine circovirus 2 (PCV-2) genotype update and proposal of a new genotyping methodology</article-title><source>PLoS ONE</source><year>2008</year><volume>13</volume><elocation-id>e0208585</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0208585</pub-id><pub-id pub-id-type="pmid">30521609</pub-id><pub-id pub-id-type="pmcid">PMC6283538</pub-id></element-citation></ref><ref id="B5-vaccines-13-00951"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pieters</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>D.</given-names></name></person-group><article-title>Mycoplasmosis</article-title><source>Diseases of Swine</source><edition>11th ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Zimmerman</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Karriker</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>G.W.</given-names></name></person-group><publisher-name>Wiley-Blackwell</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2019</year><fpage>863</fpage><lpage>883</lpage></element-citation></ref><ref id="B6-vaccines-13-00951"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beach</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Ramamoorthy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.J.</given-names></name></person-group><article-title>Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs</article-title><source>Vaccine</source><year>2010</year><volume>29</volume><fpage>221</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">21044670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2010.10.050</pub-id></element-citation></ref><ref id="B7-vaccines-13-00951"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Inactivated chimeric porcine circovirus (PCV) 1&#8211;2 vaccines based on genotypes 2b and 2d exhibit similar immunological effectiveness in protecting pigs against challenge with PCV2b strain 0233</article-title><source>Arch. Virol.</source><year>2017</year><volume>162</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-3099-x</pub-id><pub-id pub-id-type="pmid">27722993</pub-id></element-citation></ref><ref id="B8-vaccines-13-00951"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Halbur</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Matzinger</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.J.</given-names></name></person-group><article-title>Commercial PCV2a-based vaccines are effective in protecting naturally PCV2b-infected finisher pigs against experimental challenge with a 2012 mutant PCV2</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>4342</fpage><lpage>4348</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.004</pub-id><pub-id pub-id-type="pmid">24929119</pub-id></element-citation></ref><ref id="B9-vaccines-13-00951"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name><name name-style="western"><surname>O&#8217;Neill</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>de Castro</surname><given-names>A.M.M.G.</given-names></name><name name-style="western"><surname>Gimen&#233;z-Lirola</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Halbur</surname><given-names>P.G.</given-names></name></person-group><article-title>A PCV2 vaccine based on genotype 2b is more effective than a 2a-based vaccine to protect against PCV2b or combined PCV2a/2b viremia in pigs with concurrent PCV2, PRRSV PPV Infection</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.030</pub-id><pub-id pub-id-type="pmid">23174198</pub-id></element-citation></ref><ref id="B10-vaccines-13-00951"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name></person-group><article-title>Porcine circovirus 2 genotypes, immunity and vaccines: Multiple genotypes but one single serotype</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>1049</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9121049</pub-id><pub-id pub-id-type="pmid">33327478</pub-id><pub-id pub-id-type="pmcid">PMC7764931</pub-id></element-citation></ref><ref id="B11-vaccines-13-00951"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karuppannan</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name></person-group><article-title>Porcine circovirus type 2 (PCV2) vaccines in the context of current molecular epidemiology</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>99</elocation-id><pub-id pub-id-type="doi">10.3390/v9050099</pub-id><pub-id pub-id-type="pmid">28481275</pub-id><pub-id pub-id-type="pmcid">PMC5454412</pub-id></element-citation></ref><ref id="B12-vaccines-13-00951"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dinh</surname><given-names>P.X.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Le</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N.T.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.T.</given-names></name><etal/></person-group><article-title>Porcine circovirus genotypes and their copathogens in pigs with respiratory disease in southern provinces of Vietnam</article-title><source>Arch. Virol.</source><year>2021</year><volume>166</volume><fpage>403</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1007/s00705-020-04878-y</pub-id><pub-id pub-id-type="pmid">33392818</pub-id></element-citation></ref><ref id="B13-vaccines-13-00951"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.U.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Je</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Lyoo</surname><given-names>Y.S.</given-names></name></person-group><article-title>Genotypic diversity of porcine circovirus type 2 (PCV2) and genotype shift to PCV2d in Korean pig population</article-title><source>Virus Res.</source><year>2017</year><volume>228</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.11.015</pub-id><pub-id pub-id-type="pmid">27867029</pub-id></element-citation></ref><ref id="B14-vaccines-13-00951"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thangthamniyom</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sangthong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Poolperm</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thanantong</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boonsoongnern</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hansoongnern</surname><given-names>P.</given-names></name><name name-style="western"><surname>Semkum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petcharat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lekcharoensuk</surname><given-names>P.</given-names></name></person-group><article-title>Genetic diversity of porcine circovirus type 2 (PCV2) in Thailand during 2009&#8211;2015</article-title><source>Vet. Microbiol</source><year>2017</year><volume>208</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2017.08.006</pub-id><pub-id pub-id-type="pmid">28888644</pub-id></element-citation></ref><ref id="B15-vaccines-13-00951"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Chiou</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.N.</given-names></name></person-group><article-title>Phylogeographic and genetic characterization of porcine circovirus type 2 in Taiwan from 2001&#8211;2017</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><elocation-id>10782</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-47209-1</pub-id><pub-id pub-id-type="pmid">31346205</pub-id><pub-id pub-id-type="pmcid">PMC6658515</pub-id></element-citation></ref><ref id="B16-vaccines-13-00951"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.U.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name></person-group><article-title>Phylogenetic and genetic variation analyses of porcine circovirus type 2 isolated from China</article-title><source>Transbound. Emerg. Dis.</source><year>2018</year><volume>65</volume><fpage>e383</fpage><lpage>e392</lpage><pub-id pub-id-type="doi">10.1111/tbed.12768</pub-id><pub-id pub-id-type="pmid">29150903</pub-id></element-citation></ref><ref id="B17-vaccines-13-00951"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>Experimental efficacy of a trivalent vaccine containing porcine circovirus types 2a/b (PCV2a/b) and <italic toggle="yes">Mycoplasma hyopneumoniae</italic> against PCV2d and <italic toggle="yes">M. hyopneumoniae</italic> challenges</article-title><source>Vet. Microbiol.</source><year>2021</year><volume>258</volume><elocation-id>109100</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2021.109100</pub-id><pub-id pub-id-type="pmid">33984792</pub-id></element-citation></ref><ref id="B18-vaccines-13-00951"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>Synergistic pathogenicity in sequential coinfection with <italic toggle="yes">Mycoplasma hyorhinis</italic> and porcine circovirus type 2</article-title><source>Vet. Microbiol.</source><year>2016</year><volume>182</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2015.11.003</pub-id><pub-id pub-id-type="pmid">26711038</pub-id></element-citation></ref><ref id="B19-vaccines-13-00951"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaver</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>S.</given-names></name><name name-style="western"><surname>McKiernan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bain</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>R.</given-names></name></person-group><article-title>2000 report of the AVMA panel on euthanasia</article-title><source>J. Am. Vet. Med. Assoc.</source><year>2001</year><volume>218</volume><fpage>669</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">11280396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2460/javma.2001.218.669</pub-id></element-citation></ref><ref id="B20-vaccines-13-00951"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gagnon</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>del Castillo</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Music</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fontaine</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>D.</given-names></name></person-group><article-title>Development and use of a multiplex real-time quantitative polymerase chain reaction assay for detection and differentiation of Porcine circovirus-2 genotypes 2a and 2b in an epidemiological survey</article-title><source>J. Vet. Diagn. Investig.</source><year>2008</year><volume>20</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1177/104063870802000503</pub-id><pub-id pub-id-type="pmid">18776085</pub-id></element-citation></ref><ref id="B21-vaccines-13-00951"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>Comparison of three commercial one-dose porcine circovirus type 2 (PCV2) vaccines in a herd with concurrent circulation of PCV2b and mutant PCV2b</article-title><source>Vet. Microbiol.</source><year>2015</year><volume>177</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2015.02.027</pub-id><pub-id pub-id-type="pmid">25790733</pub-id></element-citation></ref><ref id="B22-vaccines-13-00951"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubosson</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Conzelmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Miserez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boerlin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zimmermann</surname><given-names>W.</given-names></name><name name-style="western"><surname>H&#228;ni</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuhnert</surname><given-names>P.</given-names></name></person-group><article-title>Development of two real-time PCR assays for the detection of <italic toggle="yes">Mycoplasma hyopneumoniae</italic> in clinical samples</article-title><source>Vet. Microbiol.</source><year>2004</year><volume>102</volume><fpage>55</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2004.05.007</pub-id><pub-id pub-id-type="pmid">15288927</pub-id></element-citation></ref><ref id="B23-vaccines-13-00951"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clavijo</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rendahl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rovira</surname><given-names>A.</given-names></name></person-group><article-title>Field evaluation of a quantitative polymerase chain reaction assay for <italic toggle="yes">Mycoplasma hyorhinis</italic></article-title><source>J. Vet. Diagn. Investig.</source><year>2014</year><volume>26</volume><fpage>755</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1177/1040638714555175</pub-id><pub-id pub-id-type="pmid">25319032</pub-id></element-citation></ref><ref id="B24-vaccines-13-00951"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Olvera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sibila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mateu</surname><given-names>E.</given-names></name></person-group><article-title>Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs</article-title><source>Vet. Microbiol.</source><year>2007</year><volume>125</volume><fpage>244</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2007.06.004</pub-id><pub-id pub-id-type="pmid">17611048</pub-id></element-citation></ref><ref id="B25-vaccines-13-00951"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pogranichnyy</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Harms</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Swenson</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Sorden</surname><given-names>S.D.</given-names></name></person-group><article-title>Characterization of immune response of young pigs to porcine circovirus type 2 infection</article-title><source>Viral. Immunol.</source><year>2000</year><volume>13</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1089/vim.2000.13.143</pub-id><pub-id pub-id-type="pmid">10892995</pub-id></element-citation></ref><ref id="B26-vaccines-13-00951"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>Comparison of 3 vaccination strategies against porcine reproductive and respiratory syndrome virus, <italic toggle="yes">Mycoplasma hyopneumoniae</italic>, and porcine circovirus type 2 on 3 pathogen challenge model</article-title><source>Can. J. Vet. Res.</source><year>2018</year><volume>82</volume><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">29382967</pub-id><pub-id pub-id-type="pmcid">PMC5764041</pub-id></element-citation></ref><ref id="B27-vaccines-13-00951"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halbur</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Landgraf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eernisse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Rathje</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus</article-title><source>Vet. Pathol.</source><year>1995</year><volume>32</volume><fpage>648</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1177/030098589503200606</pub-id><pub-id pub-id-type="pmid">8592800</pub-id></element-citation></ref><ref id="B28-vaccines-13-00951"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fenaux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Halbur</surname><given-names>P.G.</given-names></name></person-group><article-title>Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with <italic toggle="yes">Mycoplasma hyopneumoniae</italic> and porcine circovirus type 2</article-title><source>Vet. Pathol.</source><year>2004</year><volume>41</volume><fpage>624</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1354/vp.41-6-624</pub-id><pub-id pub-id-type="pmid">15557072</pub-id></element-citation></ref><ref id="B29-vaccines-13-00951"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 in porcine circovirus 2-induced granulomatous inflammation</article-title><source>J. Comp. Pathol.</source><year>2004</year><volume>131</volume><fpage>121</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2004.02.001</pub-id><pub-id pub-id-type="pmid">15276851</pub-id></element-citation></ref><ref id="B30-vaccines-13-00951"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>A comparison of virulence of three porcine circovirus type 2 (PCV2) genotypes (a, b and d) in pigs singularly inoculated with PCV2 and dually inoculated with PCV2 and porcine reproductive and respiratory syndrome virus</article-title><source>Pathogens</source><year>2021</year><volume>10</volume><elocation-id>891</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10070891</pub-id><pub-id pub-id-type="pmid">34358041</pub-id><pub-id pub-id-type="pmcid">PMC8308741</pub-id></element-citation></ref><ref id="B31-vaccines-13-00951"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simionatto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Marchioro</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dellagostin</surname><given-names>O.D.</given-names></name></person-group><article-title><italic toggle="yes">Mycoplasma hyopneumoniae</italic>: From disease to vaccine development</article-title><source>Vet. Microbiol.</source><year>2013</year><volume>165</volume><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.04.019</pub-id><pub-id pub-id-type="pmid">23680109</pub-id></element-citation></ref><ref id="B32-vaccines-13-00951"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mirazo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arbiza</surname><given-names>J.</given-names></name></person-group><article-title>First identification of porcine circovirus type 2b mutant in pigs from Uruguay</article-title><source>Infect. Genet. Evol.</source><year>2015</year><volume>33</volume><fpage>320</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2015.05.023</pub-id><pub-id pub-id-type="pmid">26004195</pub-id></element-citation></ref><ref id="B33-vaccines-13-00951"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chae</surname><given-names>C.</given-names></name></person-group><article-title>Genetic and antigenic characterization of a newly emerging porcine circovirus type 2b mutant first isolated in cases of vaccine failure in Korea</article-title><source>Arch. Virol.</source><year>2014</year><volume>159</volume><fpage>3107</fpage><lpage>3111</lpage><pub-id pub-id-type="doi">10.1007/s00705-014-2164-6</pub-id><pub-id pub-id-type="pmid">25034669</pub-id></element-citation></ref><ref id="B34-vaccines-13-00951"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opriessnig</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Halbur</surname><given-names>P.G.</given-names></name></person-group><article-title>Emergence of a novel mutant PCV2b variant associated with clinical PCVAD in two vaccinated pig farms in the U.S. concurrently infected with PPV2</article-title><source>Vet. Microbiol.</source><year>2013</year><volume>163</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2012.12.019</pub-id><pub-id pub-id-type="pmid">23305615</pub-id></element-citation></ref><ref id="B35-vaccines-13-00951"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krakowka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Felsburg</surname><given-names>P.</given-names></name></person-group><article-title>Gnotobiotics and immunopathology: The use of the gnotobiotic environment to study acquired and inherited immunodeficiency diseases</article-title><source>Vet. Immunol. Immunopathol.</source><year>2005</year><volume>108</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2005.07.019</pub-id><pub-id pub-id-type="pmid">16112740</pub-id></element-citation></ref><ref id="B36-vaccines-13-00951"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olvera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sibila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calsamiglia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name><name name-style="western"><surname>Domingo</surname><given-names>M.</given-names></name></person-group><article-title>Comparison of porcine circovirus type 2 load in serum quantified by a real time PCR in postweaning multisystemic wasting syndrome and porcine dermatitis and nephropathy syndrome naturally affected pigs</article-title><source>J. Virol. Methods</source><year>2004</year><volume>117</volume><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2003.12.007</pub-id><pub-id pub-id-type="pmid">15019262</pub-id></element-citation></ref><ref id="B37-vaccines-13-00951"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sibila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nofrar&#237;as</surname><given-names>M.</given-names></name><name name-style="western"><surname>P&#233;rez-Mart&#237;n</surname><given-names>E.</given-names></name><name name-style="western"><surname>Olvera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mateu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Segal&#233;s</surname><given-names>J.</given-names></name></person-group><article-title>Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine</article-title><source>Vet. Immunol. Immunopathol.</source><year>2012</year><volume>150</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2012.09.001</pub-id><pub-id pub-id-type="pmid">23010221</pub-id></element-citation></ref><ref id="B38-vaccines-13-00951"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Morganti</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bonilauri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guazzetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caleffi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borghetti</surname><given-names>P.</given-names></name></person-group><article-title>One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions</article-title><source>Vet. Microbiol.</source><year>2011</year><volume>149</volume><fpage>339</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2010.12.008</pub-id><pub-id pub-id-type="pmid">21216540</pub-id></element-citation></ref><ref id="B39-vaccines-13-00951"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meerts</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van-Gucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Correlation between type of adaptive immune response against porcine circovirus type 2 and level of virus replication</article-title><source>Viral. Immunol.</source><year>2005</year><volume>18</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1089/vim.2005.18.333</pub-id><pub-id pub-id-type="pmid">16035945</pub-id></element-citation></ref><ref id="B40-vaccines-13-00951"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meerts</surname><given-names>P.</given-names></name><name name-style="western"><surname>Misinzo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>B&#248;tner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kristensen</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Correlation between the presence of neutralizing antibodies against porcine circovirus 2 (PCV2) and protection against replication of the virus and development of PCV2-associated disease</article-title><source>BMC Vet. Res.</source><year>2006</year><volume>2</volume><fpage>6</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/1746-6148-2-6</pub-id><pub-id pub-id-type="pmid">16445856</pub-id><pub-id pub-id-type="pmcid">PMC1386657</pub-id></element-citation></ref><ref id="B41-vaccines-13-00951"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thacker</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>W.R.</given-names></name></person-group><article-title>Evaluation of local and systemic immune responses induced by intramuscular injection of a <italic toggle="yes">Mycoplasma hyopneumoniae</italic> bacterin to pigs</article-title><source>Am. J. Vet. Res.</source><year>2006</year><volume>61</volume><fpage>1384</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2000.61.1384</pub-id><pub-id pub-id-type="pmid">11108184</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00951-f001" orientation="portrait"><label>Figure 1</label><caption><p>Mean genomic copy numbers of PCV2 DNA in serum samples across experimental groups. (<bold>a</bold>) PCV2a loads in Vac/Ch2a vs. UnVac/Ch2a groups. (<bold>b</bold>) PCV2d loads in Vac/Ch2d vs. UnVac/Ch2d groups. (<bold>c</bold>) PCV2d loads in Vac/Ch2dMhr vs. UnVac/Ch2dMhr groups. Variation is expressed as the standard deviation. Different superscripts (a and b) indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) between groups within each pair.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g001.jpg"/></fig><fig position="float" id="vaccines-13-00951-f002" orientation="portrait"><label>Figure 2</label><caption><p>Mean genomic copy numbers of Mycoplasma DNA in challenged pigs. (<bold>a</bold>) <italic toggle="yes">M. hyopneumoniae</italic> (Mhp) loads in laryngeal samples of Vac/ChMhp vs. UnVac/ChMhp groups. (<bold>b</bold>) <italic toggle="yes">M. hyorhinis</italic> (Mhr) loads in nasal samples of Vac/Ch2dMhr vs. UnVac/Ch2dMhr groups. Variation is expressed as the standard deviation. Different superscripts (a and b) indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) between the two groups in each comparison.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g002.jpg"/></fig><fig position="float" id="vaccines-13-00951-f003" orientation="portrait"><label>Figure 3</label><caption><p>Immune responses against PCV2 in vaccinated and unvaccinated pigs following challenge. (<bold>a</bold>) Serum PCV2-specific antibody levels measured by ELISA in Vac/Ch2a, Vac/Ch2d, Vac/Ch2dMhr, UnVac/Ch2a, UnVac/Ch2d, and UnVac/Ch2dMhr groups. (<bold>b</bold>) Serum neutralizing antibody (NA) titers against PCV2 in the same groups. (<bold>c</bold>) Numbers of interferon-&#947;-secreting cells (IFN-&#947;-SC)/10<sup>6</sup> PBMCs in response to PCV2 antigen stimulation across the six groups. Variation is expressed as the standard deviation. Different superscripts (a and b) indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) between groups.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g003.jpg"/></fig><fig position="float" id="vaccines-13-00951-f004" orientation="portrait"><label>Figure 4</label><caption><p>Immune responses against <italic toggle="yes">Mycoplasma hyopneumoniae</italic> (Mhp) and <italic toggle="yes">M. hyorhinis</italic> (Mhr) in vaccinated and unvaccinated pigs following challenge. (<bold>a</bold>) Serum antibody levels against Mhp in Vac/ChMhp vs. UnVac/ChMhp groups. (<bold>b</bold>) IFN-&#947;-secreting cells (IFN-&#947;-SC)/10<sup>6</sup> PBMCs in response to Mhp stimulation in Vac/ChMhp vs. UnVac/ChMhp groups. (<bold>c</bold>) Serum antibody levels against Mhr in Vac/Ch2dMhr vs. UnVac/Ch2dMhr groups. (<bold>d</bold>) IFN-&#947;-secreting cells (IFN-&#947;-SC)/10<sup>6</sup> PBMCs in response to Mhr stimulation in Vac/Ch2dMhr vs. UnVac/Ch2dMhr groups. Variation is expressed as the standard deviation. Different superscripts (a and b) indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) between groups in each comparison.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g004.jpg"/></fig><fig position="float" id="vaccines-13-00951-f005" orientation="portrait"><label>Figure 5</label><caption><p>Gross pathological findings in vaccinated and unvaccinated pigs following challenge. (<bold>a</bold>) Minimal, well-demarcated, dark-red to purple firm parenchyma (arrow) in the lungs of the Vac/ChMhp group. (<bold>b</bold>) Severe, well-demarcated, dark-red to purple firm parenchyma (arrows) in the lungs of the UnVac/ChMhp group. (<bold>c</bold>) Minimal fibrinous exudate on the liver surface in the Vac/Ch2dMhr group. (<bold>d</bold>) Severe fibrinous exudate on the liver surface in the UnVac/Ch2dMhr group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g005.jpg"/></fig><fig position="float" id="vaccines-13-00951-f006" orientation="portrait"><label>Figure 6</label><caption><p>Histopathological lesions in vaccinated and unvaccinated pigs following challenge. (<bold>a</bold>) Minimal peribronchiolar lymphoid hyperplasia in the lungs of the Vac/ChMhp group. (<bold>b</bold>) Severe peribronchiolar lymphoid hyperplasia (arrows) in the lungs of the UnVac/ChMhp group. (<bold>c</bold>) Minimal lymphoid depletion in the lymphoid tissues of the Vac/Ch2dMhr group. (<bold>d</bold>) Severe diffuse lymphoid depletion with histiocytic replacement in the lymphoid tissues of the UnVac/Ch2dMhr group. (<bold>e</bold>) Minimal fibrinous perihepatic lesion in the Vac/Ch2dMhr group. (<bold>f</bold>) Severe fibrinous perihepatic lesion in the UnVac/Ch2dMhr group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-13-00951-g006.jpg"/></fig><table-wrap position="float" id="vaccines-13-00951-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00951-t001_Table 1</object-id><label>Table 1</label><caption><p>Experiment design with vaccination protocol and challenge models of porcine circovirus type 2a/d (PCV2a/d), <italic toggle="yes">Mycoplasma hyopneumoniae</italic> (Mhp), and <italic toggle="yes">M. hyorhinis</italic> (Mhr). Abbreviations: IM, intramuscular; IN, intranasal; IT, intratracheal; IP, intraperitoneal; PBS, phosphate-buffered-saline. &#8220;&#8722;&#8221; indicates no challenge of pathogen.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Groups</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Vaccination (Days of Age)</th><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Challenge (Days of Age)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCV2a</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCV2d</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mhp</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mhr</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM vaccination (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM vaccination (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM vaccination (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0 mL IT (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM vaccination (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IT and IP (42)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM PBS injection (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM PBS injection (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM PBS injection (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">7.0 mL IT (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IM PBS injection (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">3.0 mL IN (42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" rowspan="1" colspan="1">2.0 mL IT and IP (42)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0 mL IM PBS injection (21)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00951-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00951-t002_Table 2</object-id><label>Table 2</label><caption><p>Average daily weight gain (ADWG, gram/pig/day, mean &#177; standard deviation) of pigs in different groups. Comparisons were made among three groups within each challenge: Vac/Ch2a, UnVac/Ch2a, and UnVac/UnCh (PCV2a); Vac/Ch2d, UnVac/Ch2d, and UnVac/UnCh (PCV2d); Vac/ChMhp, UnVac/ChMhp, and UnVac/UnCh (<italic toggle="yes">M. hyopneumoniae</italic>); Vac/Ch2dMhr, UnVac/Ch2dMhr, and UnVac/UnCh (PCV2d and <italic toggle="yes">M. hyorhinis</italic>). <sup>a,b,c</sup> indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) within the same challenge and the same period (group 1 = Vac/Cha2a, UnVac/Ch2a/UnVac/UnCh; group 2 = Vac/Ch2d, UnVac/Ch2d, UnVac/UnCh; group 3 = Vac/ChMhp, UnVac/ChMhp. UnVac/UnCh; group 4 = Vac/Ch2dMhr, UnVac/2dMhr, UnVac/UnCh).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Groups</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Average Daily Weight Gain (Days, Unit = gram/pig/day)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21&#8211;42</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42&#8211;63</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21&#8211;63</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">166.67 &#177; 28.57</td><td align="center" valign="middle" rowspan="1" colspan="1">534.29 &#177; 43.17</td><td align="center" valign="middle" rowspan="1" colspan="1">350.48 &#177; 9.43</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">163.81 &#177; 15.53</td><td align="center" valign="middle" rowspan="1" colspan="1">486.67 &#177; 134.87</td><td align="center" valign="middle" rowspan="1" colspan="1">325.24 &#177; 81.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.67 &#177; 16.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577.14 &#177; 71.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371.9 &#177; 37.74</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">173.33 &#177; 15.28</td><td align="center" valign="middle" rowspan="1" colspan="1">520.95 &#177; 40.77</td><td align="center" valign="middle" rowspan="1" colspan="1">347.14 &#177; 21.26</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">162.86 &#177; 38.73</td><td align="center" valign="middle" rowspan="1" colspan="1">481.9 &#177; 147.52</td><td align="center" valign="middle" rowspan="1" colspan="1">322.38 &#177; 72.93</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.67 &#177; 16.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577.14 &#177; 71.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371.9 &#177;37.74</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">161.9 &#177; 42.72</td><td align="center" valign="middle" rowspan="1" colspan="1">524.76&#177; 30.38 <sup>ab</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">343.33 &#177; 21.26 <sup>ab</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">165.71 &#177; 41.34</td><td align="center" valign="middle" rowspan="1" colspan="1">380 &#177; 87.88 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">272.86 &#177; 40.46 <sup>b</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.67 &#177; 16.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577.14 &#177; 71.99 <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371.9 &#177; 37.74 <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">160.95 &#177; 33.23</td><td align="center" valign="middle" rowspan="1" colspan="1">269.52 &#177; 25.11 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">215.24 &#177; 7.82 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">158.1 &#177; 32.49</td><td align="center" valign="middle" rowspan="1" colspan="1">149.52 &#177; 60.88 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">153.81 &#177; 24.66 <sup>c</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">166.67 &#177; 16.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">577.14 &#177; 71.99 <sup>a</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">371.9 &#177; 37.74 <sup>a</sup></td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-13-00951-t003" orientation="portrait"><object-id pub-id-type="pii">vaccines-13-00951-t003_Table 3</object-id><label>Table 3</label><caption><p>Pathological outcomes (mean &#177; standard deviation) in different groups at 21 days post challenge. Comparisons were made among three groups within each challenge: Vac/Ch2a, UnVac/Ch2a, and UnVac/UnCh (PCV2a); Vac/Ch2d, UnVac/Ch2d, and UnVac/UnCh (PCV2d); Vac/ChMhp, UnVac/ChMhp, and UnVac/UnCh (<italic toggle="yes">M. hyopneumoniae</italic>); and Vac/Ch2dMhr, UnVac/Ch2dMhr, and UnVac/UnCh (PCV2d and <italic toggle="yes">M. hyorhinis</italic>). <sup>a,b,c</sup> indicate significant differences (<italic toggle="yes">p</italic> &lt; 0.05) among groups within the same organ (group 1 = Vac/Cha2a, UnVac/Ch2a, UnVac/UnCh; group 2 = Vac/Ch2d, UnVac/Ch2d, UnVac/UnCh; group 3 = Vac/ChMhp, UnVac/ChMhp. UnVac/UnCh; group 4: Vac/Ch2dMhr, UnVac/Ch2dMhr, UnVac/UnCh).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Groups</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Macroscopic Lesion</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Microscopic Lesion</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymph Node</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatic</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">2.24 &#177; 0.65 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2a</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">3.68 &#177; 0.95 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">2.52 &#177; 0.83 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2d</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">3.72 &#177; 0.63 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">13 &#177; 9.75 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">1.44 &#177; 0.95 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/ChMhp</td><td align="center" valign="middle" rowspan="1" colspan="1">37 &#177; 11.51 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">3.76 &#177; 0.62 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>b</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6 &#177; 0.55 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 &#177; 0.81 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4 &#177; 0.69 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">UnVac/Ch2dMhr</td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">2.8 &#177; 0.45 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" rowspan="1" colspan="1">4.32 &#177; 0.58 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">4.84 &#177; 0.26 <sup>a</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UnVac/UnCh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 &#177; 0 <sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn><p>NT = not tested.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>